Ventana | GenomeWeb

Ventana

The agreement gives Ventana access to results from a collaboration and licensing agreement that Transgenomic made separately with the University of Melbourne.

Horizon will develop cell lines and associated derivative reference standard material for Ventana on a project-by-project basis.

The test may help identify patients most likely to respond to Roche's new metastatic urothelial cancer drug Tecentriq, the FDA said.

The non-small cell lung cancer drug now has two FDA-approved companion tests, Abbott's FISH test and Ventana's IHC test, for identifying patients most likely to benefit from treatment.

Ventana will develop an in vitro companion diagnostic assay to identify high levels of hyaluronan in metastatic pancreatic cancer patients.

The collaboration will focus initially on early-phase studies involving Astellas' FGFR inhibitor, dubbed ASP5878.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.